Literature DB >> 11591813

CDK1-mediated phosphorylation of the RIIalpha regulatory subunit of PKA works as a molecular switch that promotes dissociation of RIIalpha from centrosomes at mitosis.

C R Carlson1, O Witczak, L Vossebein, J C Labbé, B S Skålhegg, G Keryer, F W Herberg, P Collas, K Taskén.   

Abstract

Protein kinase A regulatory subunit RIIalpha is tightly bound to centrosomal structures during interphase through interaction with the A-kinase anchoring protein AKAP450, but dissociates and redistributes from centrosomes at mitosis. The cyclin B-p34(cdc2) kinase (CDK1) has been shown to phosphorylate RIIalpha on T54 and this has been proposed to alter the subcellular localization of RIIalpha. We have made stable transfectants from an RIIalpha-deficient leukemia cell line (Reh) that expresses either wild-type or mutant RIIalpha (RIIalpha(T54E)). When expressed, RIIalpha detaches from centrosomes at mitosis and dissociates from its centrosomal location in purified nucleus-centrosome complexes by incubation with CDK1 in vitro. By contrast, centrosomal RIIalpha(T54E) is not redistributed at mitosis, remains mostly associated with centrosomes during all phases of the cell cycle and cannot be solubilized by CDK1 in vitro. Furthermore, RIIalpha is solubilized from particular cell fractions and changes affinity for AKAP450 in the presence of CDK1. D and V mutations of T54 also reduce affinity for the N-terminal RII-binding domain of AKAP450, whereas small neutral residues do not change affinity detected by surface plasmon resonance. In addition, only RIIalpha(T54E) interacts with AKAP450 in a RIPA-soluble extract from mitotic cells. Finally, microtubule repolymerization from mitotic centrosomes of the RIIalpha(T54E) transfectant is poorer and occurs at a lower frequency than that of RIIalpha transfectants. Our results suggest that T54 phosphorylation of RIIalpha by CDK1 might serve to regulate the centrosomal association of PKA during the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591813     DOI: 10.1242/jcs.114.18.3243

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  6 in total

1.  Female infertility in PDE3A(-/-) mice: polo-like kinase 1 (Plk1) may be a target of protein kinase A (PKA) and involved in meiotic arrest of oocytes from PDE3A(-/-) mice.

Authors:  Weixing Shen; Faiyaz Ahmad; Steven Hockman; John Ma; Hitoshi Omi; Nalini Raghavachari; Vincent Manganiello
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

Review 2.  A centrosomal scaffold shows some self-control.

Authors:  Ramya Varadarajan; John A Hammer; Nasser M Rusan
Journal:  J Biol Chem       Date:  2017-12-15       Impact factor: 5.157

3.  SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.

Authors:  Ahmed Ashour Ahmed; Zhen Lu; Nicholas B Jennings; Dariush Etemadmoghadam; Luisa Capalbo; Rodrigo O Jacamo; Nuno Barbosa-Morais; Xiao-Feng Le; Pablo Vivas-Mejia; Gabriel Lopez-Berestein; Geoffrey Grandjean; Geoffrey Bartholomeusz; Warren Liao; Michael Andreeff; David Bowtell; David M Glover; Anil K Sood; Robert C Bast
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

4.  Anchoring of protein kinase A-regulatory subunit IIalpha to subapically positioned centrosomes mediates apical bile canalicular lumen development in response to oncostatin M but not cAMP.

Authors:  Kacper A Wojtal; Dick Hoekstra; Sven C D van Ijzendoorn
Journal:  Mol Biol Cell       Date:  2007-05-09       Impact factor: 4.138

Review 5.  AKAP-scaffolding proteins and regulation of cardiac physiology.

Authors:  J R H Mauban; M O'Donnell; S Warrier; S Manni; M Bond
Journal:  Physiology (Bethesda)       Date:  2009-04

6.  Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia.

Authors:  Marie Rogne; Oksana Svaerd; Julia Madsen-Østerbye; Adnan Hashim; Geir E Tjønnfjord; Judith Staerk
Journal:  J Cell Mol Med       Date:  2018-03-07       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.